The Importance of Preventing Chills in Spinal Anesthesia

Oct 13, 2025 by pinkandtrash.com 142 views

Comparison of the Addition of Petidin 0.1 mg/kgBB with 0.2mg/kgBB into a 20 mg Hyperbaric Bupivacaine to Prevent Chills in Intrathecal Anesthesia

Introduction

Shivering during spinal anesthesia is a common problem that occurs in 40-60% of patients. This phenomenon can cause adverse physiological effects such as peripheral vasoconstriction, increased oxygen demand, increased carbon dioxide production, decreased arterial oxygen saturation, decreased drug metabolism, and myocardial ischemia. To overcome and prevent chills of perioperative, various interventions have been employed, including mechanical methods such as the use of intravenous heating fluids and pharmacological methods such as the use of opioid drugs, for example, petidin. This study aims to compare the effectiveness of the addition of petidine doses of 0.1 mg/kgBB and 0.2 mg/kgBB into a 20 mg hyperbaric bupivacaine in preventing chills in spinal anesthesia.

The Importance of Preventing Chills in Spinal Anesthesia

Preventing chills in spinal anesthesia is crucial to ensure patient comfort and safety during surgical procedures. Shivering can lead to various complications, including peripheral vasoconstriction, increased oxygen demand, and decreased arterial oxygen saturation. These complications can increase the risk of myocardial ischemia and other cardiovascular events. Therefore, it is essential to employ effective interventions to prevent chills in spinal anesthesia.

Research Methods

This study was conducted with the approval of the Ethics Committee, using a random design of a double disguise. A total of 160 subjects aged between 18 to 62 years with physical status 1-2 were included in this study. They underwent surgery with spinal anesthesia. Patients were divided into two groups: Group A who received the addition of petidin 0.1 mg/kgBB and group B who received petidin 0.2 mg/kgBB, each mixed with a hyperbaric bupivacaine of 20 mg. The parameters evaluated included chills, nausea, vomiting, and hemodynamic changes that were measured every 15 minutes during surgery. Data analysis was carried out by independent T test and chi-square test.

Research Result

The results showed that there were significant differences in the chills between the two groups. In group A (petidin 0.1 mg/kgBB) and group B (petidin 0.2 mg/kgBB), chills were measured at minutes 0, 15, 30, 45, 60, and 75 with the value of P <0.05, indicating that the addition of doses that are higher than petidine is more effective in reducing the occurrence of chills. However, the incidence of nausea and vomiting did not show significant differences; Group A experienced nausea and vomiting in 2 patients, while group B in 7 patients with a value of P> 0.05.

Conclusion

From the results of this study, it can be concluded that the use of intrathecal petidin at a dose of 0.2 mg/kgBB is more effective in preventing chills due to spinal anesthesia compared to a dose of 0.1 mg/kgBB. However, the two doses have a similar rate of nausea and vomiting, indicating that these side effects are not significantly affected by the petidin dose given. This discovery provides valuable information for the practice of anesthesia to increase patient comfort during surgical procedures.

Implications of the Study

The findings of this study have significant implications for the practice of anesthesia. The use of intrathecal petidin at a dose of 0.2 mg/kgBB can be an effective strategy to prevent chills in spinal anesthesia. This can lead to improved patient comfort and reduced risk of complications during surgical procedures. Furthermore, the study highlights the need for further research to determine the optimal dose and long-term effects of petidin in the context of spinal anesthesia.

Limitations of the Study

This study has several limitations. The sample size was relatively small, and the study was conducted in a single institution. Therefore, the findings may not be generalizable to other populations or settings. Additionally, the study only evaluated the effectiveness of petidin in preventing chills and did not explore other potential benefits or risks of its use.

Future Research Directions

Further research is needed to explore the optimal dose and long-term effects of petidin in the context of spinal anesthesia. Additionally, studies should be conducted to evaluate the effectiveness of petidin in preventing chills in other populations, such as patients with chronic pain or those undergoing complex surgical procedures. The findings of this study provide a valuable starting point for further research in this area.

Recommendations for Clinical Practice

Based on the findings of this study, the use of intrathecal petidin at a dose of 0.2 mg/kgBB can be an effective strategy to prevent chills in spinal anesthesia. Anesthesiologists should consider incorporating this intervention into their practice to improve patient comfort and reduce the risk of complications during surgical procedures. However, further research is needed to determine the optimal dose and long-term effects of petidin in the context of spinal anesthesia.

Conclusion

In conclusion, this study compared the effectiveness of the addition of petidine doses of 0.1 mg/kgBB and 0.2 mg/kgBB into a 20 mg hyperbaric bupivacaine in preventing chills in spinal anesthesia. The results showed that the use of intrathecal petidin at a dose of 0.2 mg/kgBB is more effective in preventing chills compared to a dose of 0.1 mg/kgBB. However, the two doses have a similar rate of nausea and vomiting. The findings of this study provide valuable information for the practice of anesthesia and highlight the need for further research to determine the optimal dose and long-term effects of petidin in the context of spinal anesthesia.
Frequently Asked Questions (FAQs) about the Addition of Petidin to Hyperbaric Bupivacaine in Preventing Chills in Intrathecal Anesthesia

Q: What is the purpose of adding petidin to hyperbaric bupivacaine in intrathecal anesthesia?

A: The purpose of adding petidin to hyperbaric bupivacaine in intrathecal anesthesia is to prevent chills, which is a common problem that occurs in 40-60% of patients undergoing spinal anesthesia. Chills can lead to various complications, including peripheral vasoconstriction, increased oxygen demand, and decreased arterial oxygen saturation.

Q: What are the benefits of using petidin in intrathecal anesthesia?

A: The benefits of using petidin in intrathecal anesthesia include:

Reduced incidence of chills
Improved patient comfort
Reduced risk of complications, such as peripheral vasoconstriction, increased oxygen demand, and decreased arterial oxygen saturation
Potential for improved outcomes, such as reduced length of hospital stay and reduced risk of postoperative complications

Q: What are the potential risks of using petidin in intrathecal anesthesia?

A: The potential risks of using petidin in intrathecal anesthesia include:

Nausea and vomiting
Respiratory depression
Hypotension
Allergic reactions

Q: What is the optimal dose of petidin to add to hyperbaric bupivacaine in intrathecal anesthesia?

A: The optimal dose of petidin to add to hyperbaric bupivacaine in intrathecal anesthesia is 0.2 mg/kgBB, as shown in the study. However, further research is needed to determine the optimal dose and long-term effects of petidin in the context of spinal anesthesia.

Q: Can petidin be used in patients with chronic pain or those undergoing complex surgical procedures?

A: While the study did not specifically evaluate the use of petidin in patients with chronic pain or those undergoing complex surgical procedures, it is possible that petidin may be effective in these populations. However, further research is needed to determine the safety and efficacy of petidin in these populations.

Q: How should petidin be administered in intrathecal anesthesia?

A: Petidin should be administered in a controlled manner, using a standardized protocol, to ensure optimal efficacy and safety. The dose of petidin should be titrated to achieve the desired effect, and the patient should be monitored closely for signs of adverse effects.

Q: What are the implications of this study for clinical practice?

A: The findings of this study have significant implications for clinical practice, including:

The use of intrathecal petidin at a dose of 0.2 mg/kgBB can be an effective strategy to prevent chills in spinal anesthesia
Anesthesiologists should consider incorporating this intervention into their practice to improve patient comfort and reduce the risk of complications during surgical procedures
Further research is needed to determine the optimal dose and long-term effects of petidin in the context of spinal anesthesia

Q: What are the limitations of this study?

A: The limitations of this study include:

The sample size was relatively small
The study was conducted in a single institution
The study only evaluated the effectiveness of petidin in preventing chills and did not explore other potential benefits or risks of its use

Q: What are the future research directions for this topic?

A: Future research directions for this topic include:

Determining the optimal dose and long-term effects of petidin in the context of spinal anesthesia
Evaluating the effectiveness of petidin in preventing chills in other populations, such as patients with chronic pain or those undergoing complex surgical procedures
Exploring the potential benefits and risks of using petidin in combination with other anesthetic agents.